作者: James Kim , Blake T. Aftab , Jean Y. Tang , Daniel Kim , Alex H. Lee
DOI: 10.1016/J.CCR.2012.11.017
关键词:
摘要: Recognition of the multiple roles Hedgehog signaling in cancer has prompted intensive efforts to develop targeted pathway inhibitors. Leading inhibitors clinical development act by binding a common site within Smoothened, critical component. Acquired Smoothened mutations, including SMO(D477G), confer resistance these Here, we report that itraconazole and arsenic trioxide, two agents use inhibit mechanisms distinct from current antagonists, retain inhibitory activity vitro context all reported resistance-conferring mutants GLI2 overexpression. Itraconazole alone or combination, growth medulloblastoma basal cell carcinoma vivo, prolong survival mice with intracranial drug-resistant SMO(D477G) medulloblastoma.